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Cells undergoing developmental, malignant, or viral-induced
transformation exhibit marked changes in the relative proportions
of their glucosphingolipids (GSLs) (Hakomori, 1986, 1996;
Radin, 1994). Tumour cells in particular appear to rely heavily on
the accumulation and/or overproduction of GSLs to ensure growth
and metastasis, and as a mechanism to evade host immune
responses (Li et al, 1995; Hakomori, 1996, 1994; Lavie et al,
1996; Olshefski and Ladisch, 1998). Novel GSLs, differing
primarily in the linkages between the different sugar and sialic
acid moieties, have also been reported in tumours (Nudelman et al,
1986; Radin, 1994), and a direct correlation between development
of multi-drug resistance and increased glucosylceramide synthesis
has been demonstrated (Lavie et al, 1996). Given that some or all
tumours appear to be dependent on overexpressed or abnormal
GSLs for growth, development and metastasis, inhibitors of GSL
synthesis have the potential to be universally effective anti-cancer
agents.
Studies of a family of GSL synthase inhibitors (‘P-drugs’)
representing analogues and homologues of PDMP (D-threo-1-
phenyl-2-decanoylamino-3-morpholino-1-propanol) have achieved
promising results both in vitro and in vivo as effective anti-
neoplastic agents (Inokuchi et al, 1987; Radin and Inokuchi, 1988;
Radin et al, 1993; Radin, 1994; Abe et al, 1995). These agents were
not only directly cytotoxic to tumour cells but also altered
numerous cell functions essential for tumour growth (Radin et al,
1993; Lavie et al, 1996). The effects have been linked to blockage
of the early steps in GSL synthesis and to the accumulation of
ceramide, which causes marked inhibition of cell growth as well as
being an essential early intermediary of both tumour necrosis factor
a (TNF-a)- and Fas-mediated apoptosis (Tepper et al, 1995). In
vitro, the most active of these inhibitors, P4 (DL-threo-1-phenyl-2-
palmitoylamino-3-pyrrolidino-1-propanol), was found to exhibit
IC50s against human cancer cell lines comparable in effectiveness to
several clinically used agents (Abe et al, 1995), suggesting that
GSLs play a constitutive role in tumour cell growth and differentia-
tion and thus are potentially useful targets for effective cancer
therapy.
Multi-drug resistant (MDR) tumour cells have been shown to be
especially sensitive to the growth-inhibiting activity of PDMP
(Rosenwald and Pagano, 1994) and the MDR effect has been
shown to be reversed by another P-drug (Lavie et al, 1996). In
vivo, GSL synthase inhibitors were found to be both well tolerated
and to effectively limit tumour growth (Inokuchi et al, 1987, 1990;
Nakagawa et al, 1998).
The present study was designed to identify functional and
phenotypic alterations induced by the GSL synthase inhibitor, P4,
on 5T33 murine myeloma cells. This cell line serves as a well-
characterized animal model of human multiple myeloma (Radl et
al, 1988; Manning et al, 1992). Multiple myeloma is an incurable
B-cell malignancy which accounts for >20% of all human haema-
tological cancers (Greipp, 1992). Although new treatment regi-
mens incorporating bone marrow transplantation achieve 5 times
higher complete remission rates and prolonged overall survival
compared to conventional therapy, i.e. melphalan and pred-
nisolone, relapse due to residual disease is inevitable, with a
median survival of 36 months (Cremer et al, 1997). The effects of
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P4 on cell growth, metabolism, clonogenicity and antigen expres-
sion were determined in vitro prior to conducting in vivo studies
addressing the therapeutic efficacy and immunization potential of
this inhibitor in mice. The results reported below demonstrate the
cytotoxic and cytostatic potential of P4 in this system.
MATERIALS AND METHODS
5T33 murine multiple myeloma cell line
The cells were maintained in RPMI-1640 medium (Flow
Laboratories, Irvine, UK) containing 10% fetal calf serum (FCS;
Gibco, Gaithersburg, MD, USA), 2 mML -glutamine, 100 mM
sodium pyruvate, 100 mM non-essential amino acids, penicillin
sodium salt (5000 U ml–1)/streptomycin sulphate (5 mg ml–1)
(Trace Biosciences, Castle Hill, NSW, Australia), and 50 mM
2-mercaptoethanol as previously described (Manning et al, 1992).
All cells were shown to be free of Mycoplasma by the polymerase
chain reaction (PCR) assay.
P4
The inhibitor was from Matreya, Inc. (Pleasant Gap, PA, USA). It
was stored as a 5 mM stock solution in sterile, fatty acid-poor
bovine serum albumin (BSA)/saline (molar ratio of 5:1, P4:BSA).
MTT assay
3-(4,5-dimethylthiazo-2-YL)-2,5-diphenyltetrazolium bromide
(MTT) was from Sigma Chemical Co. (St Louis, MO, USA) and
the metabolic assay was performed according to the method of
Mosmann (1983). Briefly, 2.5 ´ 104 tumour cells in 0.1 ml were
incubated overnight in 96-well, flat-bottomed microtitre plates
(Disposable Products Pty Ltd., Adelaide, SA, Australia) and then
exposed to 0–12 mM P4 (total volume 0.2 ml) for 4 days. The
plates were centrifuged (1000 g for 5 min) and 0.1 ml of the super-
natant was removed. An aliquot of 30 ml of MTT in phosphate-
buffered saline (PBS) (5 mg ml–1) was added to each well and the
plates were incubated at 37°C for 4–6 h. Extraction buffer (15%
sodium dodecyl sulphate (SDS) in 50% v/v sterile water:
dimethylformamide; pH 4.7; 0.1 ml) was then added to each well
and the plates were incubated overnight at 37°C. Absorbances
were determined at 595 nm using a BioRad Model 450 microplate
reader (Hercules, CA, USA). They were shown to be directly
proportional to cell numbers, achieving an R2 of 0.994 over a
range of 250–50 000 5T33 myeloma cells well–1 (Manning et al,
1995). The P4 concentrations required to inhibit tumour cell
growth by 50% (EC50) and by 90% (EC90) were determined from
the linear portion of the growth inhibition curve (Figure 1).
To assess the recovery of myeloma cell growth following P4
exposure, the cells were first incubated with 0–4 mM P4 in 75 cm2
tissue culture flasks (Corning Costar Corp., Cambridge, MA,
USA) for 3 days, then washed and counted by haemacytometer.
Viability was checked by trypan blue exclusion. Viable cells
(2.5  ´ 104 well–1) were then seeded into 96-well microtitre plates
and assessed for proliferation by virtue of their metabolic activity
after 5 days in inhibitor-free medium, using the MTT assay as
described above (Manning et al, 1995).
Methylcellulose assay
To assess the clonogenic potential of P4-treated cells, the cells
were treated as above and diluted to 300 cells ml–1 in 2´
Dulbecco’s modified Eagles medium (DMEM; Flow Labs.)
containing 20% FCS. Methylcellulose (Fluka Methocel 65HG,
Buchs, Switzerland) was prepared as described by Klinken (1988).
Equal volumes of cell suspension and methylcellulose solution (at
37°C) were mixed and 2 ml aliquots were added to triplicate wells
of a 24-well plate (Costar). Colonies were counted after incubation
at 37°C for 12–14 days.
Apoptosis detection
Cells were treated with 0–4 mM P4 for 3 days at 37°C, washed,
counted and the apoptotic cells detected by virtue of their ability to
bind annexin V and exclude propidium iodide (PI). These assays
were performed using an R&D Systems Apoptosis Detection Kit
(Minneapolis, MN, USA) following the manufacturer’s instruc-
tions. Cells were analysed using a Coulter EPICS XL-MCL (Flow
Cytometry Section, Division of Laboratory Medicine, Royal Perth
Hospital) with gates set at 101 log fluorescence for PI and 102 log
fluorescence for fluorescein isothiocyanate (FITC)–annexin V.
Five thousand cells were counted for each sample. The data are
presented as the percent viable (unstained) cells, cells undergoing
necrosis (stained with both FITC–annexin V and PI) or cells
undergoing apoptosis (stained with FITC–annexin V only).
Phenotypic analysis
The effects of P4 on cell surface expression of differentiation anti-
gens (H-2 Class I, H-2 Class II and CD45), adhesion molecules
(CD44 and CD54) and the IgG2b paraprotein were examined by
incubating the cells with 0–4 mM P4 for 3 days, and assessing
surface antigen expression using optimum concentrations (deter-
mined by titration) of the following antibodies: mouse anti-mouse
H-2 pan Class I (kindly provided by Dr P Price, Department of
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Figure 1 A representative growth inhibition curve. Cells were incubated
with P4 for 4 days and assessed for growth inhibition using the MTT assay
as described in Materials and Methods. The data are presented as the mean
absorbance at 595 nm (± s.d.) for quadruplicate wells in the presence of
increasing concentrations of P4. Short dash lines indicate the linear portion
of the curve with the broad dash lines representing the IC50 and IC90
determinations for this experiment. n = 20 experiments954 LS Manning and NS Radin
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Immunology, Royal Perth Hospital, Perth, WA, Australia), rat anti-
mouse H-2 I-A and rat anti-mouse CD45 (both from Serotec Ltd.,
Oxford, UK), rat anti-mouse CD44 and rat anti-mouse ICAM-1
(CD54) (both from R&D Systems), and rat anti-mouse IgG2b
(Biosource Int., Camarillo, CA, USA). Antibody binding was
detected using a biotinylated goat F(ab´)2 anti-rat Ig followed
by a streptavidin–fluorescein conjugate (both obtained from
Biosource). For each sample, 10 000 cells were analysed using the
Coulter EPICS.
Statistical analysis
Data were analysed using the two-tailed, paired Student’s t-test
and are presented as the mean ± standard deviation (s.d.) or
standard error of the mean (s.e.m.).
RESULTS
Inhibition of 5T33 myeloma cell growth by P4
P4 effectively inhibited cell growth, demonstrating an IC50 of
3.9 ± 0.3 mM for 20 experiments. A representative growth inhibi-
tion curve is shown in Figure 1. Growth inhibition of the cells
occurred over a small P4 concentration range, with the IC90
achieved at only slightly higher concentration than the IC50,
i.e. 7.1 ± 0.3 mM.
Kinetics of P4-induced growth inhibition
Significant growth inhibition was achieved by incubating cells in
the presence of only 1 mM P4 (Figure 2). Viable cell recovery was
reduced from 18 ± 2 ´ 106 for untreated cells to 1.5 ± 0.1 ´ 106 for
cells exposed to 4 mM P4 for 3 days (92% reduction). These
remaining cells represent only 50% of the starting cell number (i.e.
3 ´ 106 flask–1) suggesting that a large proportion of the tumour
cells are actually being destroyed by P4. As day 4 control cultures
demonstrated reduced cell recovery as compared to day 3, prob-
ably due to nutrient and GSL depletion, all remaining experiments
were conducted using cells exposed to P4 for 3 days.
Effects of P4 on 5T33 myeloma cell functional activities
Table 1 depicts the effects of P4 on various functional parameters
essential for tumour growth and development. Inhibition of all
parameters tested was found to be dose-dependent with the IC50
concentration (i.e. 4 mM) reducing functional activities by
45–88%. Both cytostatic and cytotoxic growth inhibition were
observed. Significant cytostatic inhibition was observed at the
lowest concentration of P4 tested (0.5 mM) with cell recovery and
proliferation reduced by 21% and 28% respectively (P < 0.001). In
contrast, significant loss of cell viability, indicative of cytotoxic
activity, was only achieved at the higher concentrations of P4, 3–
4 mM (P < 0.001). Exposure of the cells to 4 mM P4 for 3 days
reduced cell viability by 45%. The same concentration decreased
cell recovery by 87% (P < 0.001). As shown in Figure 2, cell
recovery following 4 mM P4 treatment was actually 33% less than
the starting cell number (2 vs 3 ´ 106 cells; Table 1) resulting in a
negative proliferation index for these cultures (–0.4). These find-
ings further support direct tumour cell lysis by P4 in addition to its
cytostatic activity.
Using metabolic activity as a measure of cell numbers, P4
exposure was found to significantly decrease myeloma cell growth
with 4 mM P4 reducing metabolic activity by 58% compared to
Table 1 Effects of P4 on 5T33 myeloma cell functional parameters
P4 concentration (mM)
0 0.5/1a 23 4
Functional parameter mean ± s.e.m. (% of 0 control)
I. Cell recoveryb 14.9±1.0 11.7±0.7* 8.5±0.5* 5.0±0.6* 2.0±0.6*
´ 106 cells (100%) (78.6%) (56.8%) (33.5%) (13.3%)
II. Cell proliferationc 5.4±0.4 3.9±0.3* 3.0±0.3* 1.7±0.3* –0.4±0.4*
fold change in cell #s (100%) (72.2%) (55.6%) (31.5%) (–92%)
III. Viabilityd 93.9±0.7 91.1±1.4 88.9±1.6 76.1±3.4* 52.1±6.6*
% viable cells (100%) (96.9%) (94.7%) (81.0%) (55.3%)
IV. Regrowth potentiale 1.18±0.07 1.00±0.08 0.85±0.08* 0.65±0.08* 0.44±0.04*
(100%) (93.9%) (78.8%) (64.1%) (41.7%)
V. Clonogenic potentialf 43.4±5.2 26.1±5.1* 20.0±3.1* 13.2±3.1* 5.4±2.4*
# of clones well–1 (100%) (60.1%) (45.9%) (27.6%) (13.9%)
Cells were incubated for 3 days in the presence of 0–4 mM P4, washed and assessed for functional activity. N = 10 experiments for each parameter. aNo
difference was observed for cells treated with 0.5 or 1 mM P4, so the data have been pooled. bCell recovery was determined by cell counting using a
haemacytometer. The data are presented as the mean number of viable cells recovered ± s.e.m. The values in parentheses represent the % cell recovery
compared to untreated cells. cCell proliferation during the 3-day incubation period was calculated from the starting cell number flask–1, i.e. 3 ´ 106 cells. The data
are presented as the mean fold change in cell numbers ± s.e.m. The values in parentheses represent the % cell proliferation compared to untreated cells. dCell
viability was determined by trypan blue exclusion. The data are presented as the mean % viable cells ± s.e.m. The values in parentheses represent the % viable
cells compared to untreated cells. eThe regrowth potential of P4-treated cells was determined using the MTT assay as described in Materials and Methods. The
data are presented as the mean absorbance at 595 nm ± s.e.m. The values in parentheses represent the % regrowth potential compared to untreated cells.
fThe clonogenic potential of P4-treated cells was determined by colony formation in methylcellulose as described in Materials and Methods. The data are
presented as the mean number of colonies well–1 ± s.e.m. The values in parentheses represent the % number of colonies compared to untreated cells. The
clonogenic potential of untreated 5T33 myeloma cells ranged from 10.8 to 18.2%. *P < 0.001 compared to untreated cells.Effects of the glucolipid inhibitor, P4, on murine myeloma cells 955
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untreated cells (Table 1; P < 0.001). The clonogenic potential of
the cells was even more sensitive to the inhibitory effects of P4
with exposure to 0.5 mM P4 inducing a 40% decrease in clonogenic
potential (from 43 ± 5 to 26 ± 5 colonies well–1; P < 0.001). The
IC50 concentration (4 mM) of P4 inhibited colony formation by
86% (P < 0.001).
Induction of apoptosis by P4
The dose-dependent loss of viability observed for P4-treated cells
was found to be due both to necrosis and to apoptosis (Figure 3).
At lower concentrations of P4 (0.5–1 mM), the increase in necrotic
cells alone (from 4 ± 0.4% to 10 ± 1%) did not significantly
decrease cell viability, which supports the viability results shown
in Table 1. However, 15 ± 1% of the cells treated with 0.5 mM P4
were found to be undergoing apoptosis (Figure 3). This represents
a population of ‘non-viable’ cells that would not be detected by the
trypan blue assay, suggesting that even at low P4 concentrations, a
significant number of the cells are programmed for cell death. Cell
viability was reduced from 88 ± 1% to 48 ± 1% following
exposure to 4 mM P4 for 3 days with 26 ± 2% of the non-viable
cells undergoing apoptosis (Figure 3; P < 0.001).
Effects of P4 on surface antigen expression
The effects of P4 treatment on expression of cell surface antigens
involved in differentiation, adhesion and immunogenicity were
evaluated as potential markers of functional alterations. Both the
Class I and Class II antigen presentation molecules demonstrated
dose-dependent alterations in cell surface expression following
incubation with P4 (Table 2). Myeloma cell exposure to as little as
2 mM P4 was sufficient to reduce the number of cells expressing
the Class I antigen from 95 ± 1% to 87 ± 1% (P < 0.001), with
4 mM P4 decreasing this number even further. Surface expression
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Figure 2 Kinetics of P4-induced growth inhibition on 5T33 myeloma cell
survival. Cells were incubated in the presence of 0–4 mM P4 for 1–4 days and
assessed for viable cell recovery as described in Materials and Methods. The
data are presented as the mean viable cells ´ 106 (± s.d.) for duplicate flasks
for 3 experiments. Starting cell concentration = 3 ´ 106 cells flask–1
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Figure 3 Dose-dependent induction of apoptosis in 5T33 myeloma cells by
P4. Cells were incubated in the presence of 0–4 mM P4 for 3 days, washed
and assessed for apoptosis as described in Materials and Methods. The data
are presented as the percentage (± s.e.m.) of viable cells (n); necrotic cells
( ) and cells undergoing apoptosis ( ). n = 7 experiments. P < 0.01 for all
three cell populations compared to untreated cells
Table 2 Effects of P4 on 5T33 myeloma cell phenotypic parameters
P4 concentration (mM)
0 0.5/1a 234
Phenotypic parameter mean % fluorescing cells ± s.e.m.
I. Differentiation Ags
H-2 Class I 94.5±0.7 90.9±1.4 87.4±1.4* 77.5±2.3* 61.4±3.7*
H-2 Class II 1.7±0.4 3.0±0.9 6.0±1.2* 8.6±2.2* 14.1±2.7*
CD45 89.9±1.4 90.6±1.0 88.0±1.8 88.5±1.8 89.9±2.0
II. Adhesion molecules
CD44 89.5±1.6 80.0±2.1 72.8±3.0* 59.5±3.7* 38.0±2.3*
CD54 92.9±0.9 90.9±1.1 91.7±1.0 89.6±4.0 93.3±0.3
III. Paraprotein
IgG2b 5.6±0.8 8.2±0.9 13.8±1.0* 18.8±2.2* 26.9±3.6*
Cells were incubated for 3 days in the presence of 0–4 mM P4, washed and assessed for cell surface antigen expression. The data are presented as the mean
% fluorescing cells ± s.e.m. for 6–10 experiments for each antigen. Fluorescence was detected using the Coulter EPICS flow cytometer and 10 000 cells
(events) were analysed for each sample. aNo difference was observed for cells treated with 0.5 or 1 mM P4 so the data have been pooled. *P < 0.001 compared
to untreated cells.956 LS Manning and NS Radin
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of Class I was observed on only 61 ± 4% of cells following treat-
ment with 4 mM P4 (Table 2; P < 0.001). In complete contrast,
Class II antigen expression was markedly increased by the
inhibitor, with 4 mM P4 increasing expression almost tenfold (from
2 ± 0.4% to 14 ± 3%; P < 0.001). Approximately 90% of the cells
were found to express the differentiation antigen, CD45, which is a
marker for primitive to immature plasma cells/myeloma cells
(Schneider et al, 1997), and this expression was not altered by P4
exposure regardless of the inhibitor concentration (Table 2).
CD44 has been shown to be an important adhesion molecule for
myeloma cell homing to the bone marrow and binding to bone
marrow stromal cells, whereas CD54 (ICAM-1) appears to play
only a minor role in this aspect of disease development (Okada and
Hawley, 1995). Of interest, P4 was found to induce a striking dose-
dependent decrease in CD44 expression without altering CD54
expression (Table 2). Whereas 90 ± 2% of untreated cells
expressed CD44, only 38 ± 2% of cells exposed to 4 mM P4 main-
tained surface expression of this antigen (P < 0.001). ICAM-1
(CD54) expression, on the other hand, was observed on > 90% of
all the cells tested regardless of P4 exposure. These results imply
an important role for GSLs in CD44 function.
The myeloma paraprotein has been shown to be a highly
immunogenic molecule capable of inducing therapeutically effec-
tive anti-idiotypic immune responses in both mice and humans
(Croese et al, 1991a, 1991b; Kwak et al, 1995). P4 exposure was
found to induce a large, dose-dependent increase in the number
of cells expressing IgG2b (Table 2). Only 5.6 ± 0.8% of untreated
cells expressed the paraprotein on their surface compared to
26.9  ± 3.6% of cells exposed to 4 mM P4 for 3 days (P < 0.001).
DISCUSSION
The pattern of growth inhibition observed for P4 on the 5T33
murine myeloma cells used in this study (Figure 1) was similar to
those previously reported for this and other ‘P-drugs’ against five
types of human malignancy (Abe et al, 1995). The 3.9 mM IC50 P4
concentration is comparable to those reported for the human cell
lines (IC50s of 0.7–2.6 mM). The IC90 P4 concentration was less
than twice the IC50 (i.e. 7.1 mM). P4-induced growth inhibition of
both the human and murine cell lines was found to occur over a
very small concentration range, as indicated by the steep slopes of
the growth inhibition curves (Abe et al, 1995; Figure 1). The
uniformity of inhibitor activity observed against the various
tumour types provides additional evidence that GSLs play a
constitutive role in tumour cell growth and differentiation. It also
suggests that GSL synthase inhibitors may have a wider thera-
peutic application than currently used cytotoxic drugs. The fact
that P-drugs have been shown to be effective against MDR tumour
cells (Rosenwald and Pagano, 1994; Lavie et al, 1996) is of partic-
ular interest given that disease relapse due to the emergence of
drug-resistant cells remains the leading cause of death of patients
with many types of tumours, including multiple myeloma.
Because the 5T33 murine myeloma cells do not express surface
P-glycoprotein 170 (P-gp170; data not shown), human myeloma
cells of known MDR phenotype will be used to address this impor-
tant issue.
Several tumour cell functions were found to be markedly down-
regulated at P4 concentrations (0.5–1 mM), which induced only
minimal cytotoxicity (Table 1). A significant reduction in cell
recovery following 3 day incubation with P4 was observed at the
lowest concentration of P4 tested (0.5 mM), apparently a reflection
of a reduction in both cell proliferation and metabolic activity.
Clonogenic potential was also significantly reduced by exposure to
low-dose P4, whereas tumour cell viability was not altered under
these conditions (Table 1). Significant loss of tumour cell viability,
as determined by trypan blue uptake, was only observed following
incubation with 3–4 mM P4 (Table 1). In fact, cell recovery was
reduced by > 33% of starting cell numbers under these conditions
suggesting direct cytolysis of a substantial number of tumour cells
by high-dose P4. This dose-dependent distinction between reduced
cell growth and induced cell death by GSL synthase inhibitors has
been previously reported (Inokuchi et al, 1990; Rosenwald and
Pagano, 1994; Abe et al, 1995). It is likely that cells engage in a
‘yin and yang’ competition, in which the proliferative effects of
glucosylceramide oppose the repressive apoptotic effects of its
precursor, ceramide.
The impaired growth and clonogenic potential we observed in
treated cells even after the cells were transferred to normal
medium, may be the result of retention of P4 by the cells. A test
with Madin–Darby canine kidney cells showed, by chromato-
graphic analysis and enzyme assay, that P4 does not readily leave
P4-treated cells, even when the cells are homogenized and washed
(Abe et al, 1996). This prolonged action would have the advantage
of maintaining viable, non-replicating tumour cells as targets for
immune activation. It also suggests that frequent dosing of P4 in a
cancer-bearing patient may not be necessary to maintain thera-
peutic efficacy.
This study identified a dose-dependent increase in cells under-
going apoptosis; which may play a significant role in both the
reduced tumour cell recovery and viability observed following P4
exposure (Table 1 and Figure 3). At the lower concentrations of P4
(0.5–1 mM), the increase in necrotic cells alone was not sufficient
to significantly reduce tumour cell viability (95% to 89%), which
correlates with the previous trypan blue exclusion results (Table
1). However, a substantial increase in cells undergoing apoptosis
was identified by flow cytometry (from 7% to 15%; Figure 3).
Significant cytotoxicity was observed following cell exposure to
4 mM P4 for 3 days, with necrotic cells increasing to > 23% of the
tumour cell population (Figure 3). An additional 26% of the cells
were programmed for cell death, i.e. undergoing apoptosis, which
indirectly supports the concept of inhibitor-induced accumulation
of ceramide (Figure 3). Abe et al (1995) clearly showed ceramide
accumulation at this concentration of P4. Overall, the population
defined as ‘viable’ by this assay was reduced to 55% of control
cells under these conditions. These results suggest that in addition
to being directly toxic to tumour cells, high-dose glucolipid
synthase inhibitor therapy effectively limits the growth potential of
a substantial number of the ‘surviving’ cells.
Cell surface GSLs have been implicated as essential molecules
in tumour cell attachment, immune evasion and metastatic spread
(Inokuchi et al, 1990; Hakomori, 1994; Kannagi, 1997). In this
study, alterations in several cell surface molecules were readily
identified following P4 exposure. The proportion of cells
expressing surface H-2 Class I antigen was reduced by P4 in a
dose-dependent manner (Table 2). Several inhibitor-induced alter-
ations may be involved in this effect, including disruption of
receptor assembly and transport, of anchoring and presentation on
the cell surface, or of b-2-microglobulin (b-2M) production, which
is essential for Class I antigen expression (Karre, 1993; Radin et
al, 1993; Rosenwald and Pagano, 1994). Although the loss of
Class I positive tumour cells may reduce CD8+ cytotoxic T-cell
(CTL) recognition and activation, susceptibility to killing byEffects of the glucolipid inhibitor, P4, on murine myeloma cells 957
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natural killer (NK) cells should be enhanced in this setting since
Class I expression is inhibitory to NK cell function (Karre, 1993).
The immunosurveillance role of NK cells is thought to be particu-
larly important in controlling haematological malignancies and
circulating metastatic foci (Karre, 1993).
In contrast to the effect of P4 on Class I expression, the number
of cells expressing H-2 Class II was greatly increased following
P4 exposure (Table 2). Increased expression of Class II has been
shown to be a positive prognostic factor in several tumour
systems, resulting in effective immune activation and subsequent
tumour regression in some cases (Baskar et al, 1995; Cabrera et al,
1995; Armstrong et al, 1997). Experiments are currently underway
that address P4-induced activation of a tumour-specific immune
response in 5T33 myeloma-bearing mice.
The common leucocyte antigen, CD45, which has been shown to
be most highly expressed on primitive and immature plasma cells
and myeloma cells (Schneider et al, 1997), was not affected by P4
exposure. Taken together, the results suggest that tumour cells
utilize GSLs extensively, but selectively, to maximize survival.
In terms of adhesion molecules, Okada and Hawley (1995) have
demonstrated that murine myeloma cells, like human myeloma
cells, express surface CD44, ICAM-1 (CD54) and VLA-4. In addi-
tion, CD44 and VLA-4 were shown to be involved in myeloma
cell binding to bone marrow stromal cells (i.e. endothelial cells,
fibroblasts and adipocytes) with ICAM-1 only partially involved
in binding to bone marrow-derived macrophages. The present
study revealed a marked, P4-dependent decrease in cells
expressing CD44 (Table 2). This response is to be expected based
on the observation that CD44 is closely associated with GSL-rich
plasma membrane domains (Ilangumaran et al, 1998), and may
have important implications for myeloma development.
Hyaluronan, the ligand for CD44, is found in high concentration in
bone marrow (Aruffo et al, 1990) and is known to play an impor-
tant role in tumour homing and metastasis (Sherman et al, 1994). It
is possible that the loss of CD44 expression would not only inter-
fere with tumour seeding in the appropriate micro-environment,
i.e. the bone marrow, but would also relegate tumour cells to the
circulation and lymphatics, thereby increasing their exposure to
the immune system and allowing effective immune activation
prior to tumour establishment. Experiments are currently
underway in which mice and/or tumour cells are treated with P4
prior to tumour cell inoculation to investigate inhibitor effects on
both tumour development and immune induction in vivo.
The myeloma paraprotein has been shown to be a highly
immunogenic molecule capable of inducing both tumour-specific
anti-idiotypic antibodies as well as activating idiotypic-specific
T-cells (Croese et al, 1991a, 1991b; Kwak et al, 1992, 1995;
Dabadghao et al, 1998). Here, we report a significant, dose-
dependent increase in 5T33 myeloma cells expressing surface
IgG2b paraprotein (up to 27%; Table 2). Increased expression of
this highly immunogenic antigen may enhance immune recogni-
tion with subsequent activation of a protective tumour-specific
immune response.
The results of this and many other studies strongly suggest that
GSL synthase inhibitors have the potential to be a universally
effective form of cancer treatment. Given that current therapies are
not curative for the majority of human malignancies, alternative
forms of treatment need to be developed to improve the prognosis
of patients with cancer. It is anticipated that continued investiga-
tions of both the therapeutic and immunization potential of GSL
synthase inhibitors will clarify the efficacy of these inhibitors as
novel therapeutic agents and lend themselves to the development
of more effective treatment for patients with cancer.
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